A Chinese biotech registers a semaglutide-to-zovaglutide switching trial

Beijing QL Biopharmaceutical Co., Ltd has registered a new Phase 2 trial, HORIZON-SWITCH-SZ, that will study the safety and tolerability of moving adults with obesity from semaglutide to a different GLP-1 drug called zovaglutide. The trial, listed under NCT07812597, plans to enroll 210 participants and is currently listed as "not yet recruiting" ^[1].

The registry entry does not include a start date, completion date, or specific study sites, so it is not yet known when the trial will begin enrolling patients or where it will take place ^[1]. The listing does confirm the drug comparison at the center of the study: participants already on semaglutide, the active ingredient in Ozempic, Wegovy, and Rybelsus, would be switched to zovaglutide, described in the registry as a different GLP-1 peptide ^[1].

QL Biopharm's trial is not an isolated event. The same tracking source shows Novo Nordisk registered its own switching study just days later, on 2026-09-14, testing how people with type 2 diabetes tolerate a change from semaglutide to CagriSema, also enrolling 210 participants ^[1]. Seeing two separate switching trials involving semaglutide appear in the same short window suggests that comparing a newer or differently dosed drug against the current standard is becoming a routine step for companies developing GLP-1 alternatives, though the registry entries alone do not explain each company's strategy ^[1].

Broader financing data show that obesity remains one of the therapeutic areas attracting large biotech investments right now, with investors reportedly paying for improvements in dosing, tolerability, and drug mechanism rather than for novelty alone ^[2]. That same overview notes that licensing an already-clinical Chinese drug asset has become a common way for companies to skip early discovery work and move faster into human testing ^[2]. However, the sources reviewed for this story do not contain a specific figure for how much QL Biopharm has raised around its zovaglutide program, so that detail is not confirmed here and should be treated as not yet established from available reporting.

Why it matters for patients

For people currently taking semaglutide products such as Ozempic, Wegovy, or Rybelsus, this trial registration does not change anything about their treatment today. The study has not started recruiting, so no patients are being switched as part of it yet ^[1]. Zovaglutide is not an approved drug in the United States, and the sources reviewed do not describe its regulatory status outside of this single trial listing ^[1].

What this development does show is that drugmakers are increasingly testing how patients tolerate moving from a weekly injection to a less frequent option, in this case reportedly once a month. If a monthly GLP-1 drug eventually reaches the market, switching data like this could matter to patients weighing convenience against the years of safety experience built up with weekly semaglutide. But because the study is still in an early Phase 2 stage and has not begun enrolling, any conclusions about safety or tolerability of the switch are not yet available ^[1].

What happens next

The trial remains listed as "not yet recruiting" as of the most recent registry snapshot reviewed, with no enrollment start date, completion date, or results timeline yet disclosed ^[1]. Patients and clinicians interested in this program will need to watch for a status change to "recruiting" before enrollment or site information becomes available. Separately, Novo Nordisk's own semaglutide-to-CagriSema switching study, registered the same week, will offer a parallel comparison point as both trials move forward ^[1].